biokimia sistem kardiovaskuler

70
BIOCHEMISTRY OF BIOCHEMISTRY OF CARDIOVASCULAR SYSTEM CARDIOVASCULAR SYSTEM AGNES O. KWENANG AGNES O. KWENANG

Upload: adi-surya-syam

Post on 28-Oct-2014

281 views

Category:

Documents


5 download

TRANSCRIPT

Page 1: Biokimia Sistem Kardiovaskuler

BIOCHEMISTRY OF BIOCHEMISTRY OF CARDIOVASCULAR SYSTEMCARDIOVASCULAR SYSTEM

AGNES O. KWENANGAGNES O. KWENANG

Page 2: Biokimia Sistem Kardiovaskuler

Topic : A. Metabolic regulation in Topic : A. Metabolic regulation in cardiac muscle.cardiac muscle.

  General learning objective

Student should be able to understand the general feature of metabolism and its regulation in cardiac muscle.

Page 3: Biokimia Sistem Kardiovaskuler

Specific learning objectives

When student have mastered this topic, student should be able to:

1. explain the heart is a largely aerobic organ

2. explain myocardial energy metabolism and its regulation

3. describe cholesterol and lipoprotein turnover correlated with atherosclerosis.

Page 4: Biokimia Sistem Kardiovaskuler

IntroductionIntroduction

The heart is a largely or completely aerobic organ and contain negligible energy reserves in the form of glycogen or lipid. Therefore, the heart also must have a continuous supply of energy.

Page 5: Biokimia Sistem Kardiovaskuler

As prerequisite knowledge, we shall assume that the student has a degree of familiarity with the basic concepts of mechanism of enzyme action, metabolic pathways, electron transport chain and oxidative phosphorylation, and the role of ATP.

We shall mainly discuss about cardiac energy metabolism, the regulation of glycolysis and lipolysis.

Page 6: Biokimia Sistem Kardiovaskuler

1. The heart is a largely aerobic organ.

CARDIAC MUSCLEThe heart is a muscular organ but one that must maintain continuous rather than intermitten activity. Thus heart muscle, except for short periods of extreme exertion, relies entirely on aerobic metabolism.

Page 7: Biokimia Sistem Kardiovaskuler

It is therefore richly with mitochondria; they comprise up to 40%-50% of its cytoplasmic space, whereas some types of skeletal muscle are nearly devoid of mitochondria.

Page 8: Biokimia Sistem Kardiovaskuler

The heart can metabolize fatty acids, keton bodies, glucose, pyruvate, and lactate. The heart muscle can utilize fatty acids and lactate as energy sources in addition to glucose and ketonbodies.

Page 9: Biokimia Sistem Kardiovaskuler

Fatty acids are the resting heart’s fuel of choice but, upon the imposition of heavy work load or the work load increases dramatically, the heart greatly increases its rate of consumption of glucose or begin to use glucose, which is derived mostly from its own relatively limited glycogen store.

Page 10: Biokimia Sistem Kardiovaskuler
Page 11: Biokimia Sistem Kardiovaskuler

Fig 1.The energy the heart uses to perform pumping the blood is generated through the hydrolysis of ATP to ADP and Pi. ATP constantly generated by the mitochondria that are abundant in heart muscle cells with small amount relatively: 5 umols/g. ATP turn over rate in ATP pool is very fast : 10-15 sec.

Page 12: Biokimia Sistem Kardiovaskuler

ATP is used for contraction: 60-70%, and ATP is used for contraction: 60-70%, and 40% 40% ATP is also used for ion pump by the Ca2+-ATPase and Na+/K+-ATPase of the sarcolemma, by the Ca2+-ATPase of SR (Sarcoplasmic Reticulum) to store Ca2+ due to possibly for relaxation in diastole phase , and by biosynthetic processes.

Page 13: Biokimia Sistem Kardiovaskuler
Page 14: Biokimia Sistem Kardiovaskuler

2. Myocardial energy metabolism

MitochondriaFig 2.About 90% of the ATP is synthesized by oxidative phosphorylation from fatty acid oxidation:60-90% and glucose + lactate oxidation: 10-40% in the mitochondria and about 10% by glycolysis, that take place in the cytosol.

Page 15: Biokimia Sistem Kardiovaskuler

Mitochondria are strictly dependent on O2, they mainly oxidize fatty acids (note: of all the food we eat fat has the highest calorie value) and pyruvate arising from the glycolysis of glucose.

Page 16: Biokimia Sistem Kardiovaskuler

Mitochondrial regulation of cell function.

Situation in heart muscle.In cardiac muscle, constant contraction utilizes ATP, converting to ADP. There are large number of mitochondria in heart muscle, ensuring that oxidation by the heart is essentially always aerobic.

Campbell1982.138-139

Fig 3

Page 17: Biokimia Sistem Kardiovaskuler
Page 18: Biokimia Sistem Kardiovaskuler

The Regulation of Glucose The Regulation of Glucose OxidationOxidation

(Fig.4)

A. Activation of glucose transport into muscle by insulin or exercise.

B. Inhibition of hexokinase by its product, glucose 6-phosphate.

Page 19: Biokimia Sistem Kardiovaskuler
Page 20: Biokimia Sistem Kardiovaskuler

C. Phosphofructokinase is inhibited by ATP (not shown); the inhibition is relieved by AMP and relief is augmented by the product of the reaction, fructose 1,6-bisphosphate. The enzyme is inhibited by citrate, which enters the cytosol from mitochondria by an antiport mechanism.

Page 21: Biokimia Sistem Kardiovaskuler

D. The conversion of triose phosphates to pyruvate depends upon availability of ADP, which is also a substrate. Unless ATP is being utilized, the ADP concentration will fall and triose phosphate oxidation will slow.

Page 22: Biokimia Sistem Kardiovaskuler

E. The extent of regulation of pyruvate exchange across the inner mitochondrial membrane is not known.F. The pyruvate decarboxylase component of pyruvate dehydrogenase is inactivated by phosphorylation. Phosphorylation is accelerated by NADH or acetyl coenzyme A, and is inhibited by ADP.G. The citric acid cycle, as well as the electron transport shuttles, hinges upon the availability of ADP to maintain oxidative phosphorylation (not shown).(Fig.5).

Goldstein,1983,3ed,478-479.

Page 23: Biokimia Sistem Kardiovaskuler

Acetyl ko.a

citrate

IsocitrateOxaloacetate

NADH→ (-)ADP (+)

NAD+

NADH *α - ketoglutarate

succinylcoa

CoASH

(-)

NAD+

NADH*

CoASH

GTP GDPsuccinate

Fumarate

Malate

QH2

Q*

NAD+

NADH

*

(-)

Page 24: Biokimia Sistem Kardiovaskuler

The Regulation of the Citric Acid The Regulation of the Citric Acid CycleCycle

Since the CAC is in the major routes of fuel combustion in many cells, there must be some control of the rate at which it proceeds (Fig.4). It wouldn’t do to have the oxidative machinery going full tilt like a runaway boiler at times of rest nor would it to do to have it only sluggishly responsive when there is an immediate demand for ATP.

Page 25: Biokimia Sistem Kardiovaskuler

The starred reactions require oxidized coenzymes, and the ratio of oxidized to reduced coenzyme is governed by the availability of ADP and Pi for oxidative phosphorylation (OP). Other specific controls prevent irreversible steps in the cycle from depleting the supply of cofactors and cycle intermediates. The action of negative effectors is indicated by (-); the action of positive effector (+) is indicated by an open arrow next to the reaction arrow.

Page 26: Biokimia Sistem Kardiovaskuler

Stoichiometric Regulation by ADP.

Since a major consequence of the action of CAC is the conversion of ADP and Pi to ATP through the mechanism of OP, it follows that the cycle won’t function unless there is supply of ADP and Pi.

Page 27: Biokimia Sistem Kardiovaskuler

ADP concentration as the normal regulating factor, but it may be that the muscular weakness or impaired cardiac performance sometimes seen in patients with low Pi concentration (hypophosphatemia) is due to Pi becoming limiting. (The concentration may be lowered by prolonged use of antacids, which cause passage of insoluble phosphates through the bowel, for example)

Page 28: Biokimia Sistem Kardiovaskuler

Regulation by effectors:

a. Citrate synthase reaction.

The Km for OAA is in the physiological concentration range; furthermore, citrate is a competitive inhibitor for OAA on the enzyme. The effect is double-barreled.

Page 29: Biokimia Sistem Kardiovaskuler

An accumulation of citrate raises its concentration as an inhibitor, but it also lowers the concentration of OAA as a substrate. Why? Because the complete cycle must function at the same rate to restore the OAA consumed in the first step. Any accumulation of intermediates in the cycle represents a depletion of OAA.

Page 30: Biokimia Sistem Kardiovaskuler

b. Isocitrate dehydrogenase

Two important allosteric effects are used here. ADP is a specific activator which lowers the Km for isocitrate. A rise in ADP concentration is a signal of a need for more high-energy phosphate, and the response to this signal includes an accelerated injection of substrate into the CAC.

Page 31: Biokimia Sistem Kardiovaskuler

Isocitrate dehydrogenase is also inhibited by NADH at an allosteric site. Any slowing of OP, which leads to an accumulation of NADH, therefore slows the enzyme in two ways. If the [NADH] is high, the [NAD] must be low, and NAD is required as a substrate for the reaction.

Page 32: Biokimia Sistem Kardiovaskuler

The NADH also combines with the allosteric site to make the enzyme less active. (Any control of Isocitrate dehydrogenase also tends to control citrate synthase because changes in isocitrate concentration are accompanied by changes in citrate concentration. Aconitase rapidly equilibrates the two compound)

Page 33: Biokimia Sistem Kardiovaskuler

c. -ketoglutarate dehydrogenase reaction

represents a threat to the supply of Coenzyme A (CoA) for other reaction. Indeed, 70% of the CoA supply in some tissue is present as succinyl CoA under some conditions, even though the enzyme is regulated. The compound tens to accumulate at rest when the phosphate potential is high, owing to the lack of GDP and Pi for its subsequent use.

Page 34: Biokimia Sistem Kardiovaskuler

The extent of accumulation is controlled by constructing the -KG dehydrogenase so that its product, succinyl CoA, is a competitive inhibitor for one of its substrate, CoA. Here again is a double-barrel effect. A rise in succinyl CoA concentration in itself inhibits, but it also represents a depletion of CoA, causing still more effective inhibition. (Fig 4).

Glodstein,1983,3ed.p437-439.

Page 35: Biokimia Sistem Kardiovaskuler

The Regulation of Mitochondrial The Regulation of Mitochondrial Fatty Acid OxidationFatty Acid Oxidation

The oxidation of the FAs to acetyl CoA, like The oxidation of the FAs to acetyl CoA, like the subsequent oxidation of acetyl CoA via the subsequent oxidation of acetyl CoA via the CAC, requires ADP to be available for the CAC, requires ADP to be available for coupled OP. If there is no demand for high coupled OP. If there is no demand for high energy phosphate, there is no production energy phosphate, there is no production of ADP, no electron transport, and no FA of ADP, no electron transport, and no FA oxidation. oxidation.

Page 36: Biokimia Sistem Kardiovaskuler

However, given a demand for high-energy phosphate, the primary regulation in animal appears to hinge on the amount of substrate available. The 3-oxybutyrates are preferentially used by peripheral tissues when they are available, and high concentration of the FFAs promote the formation of the keton bodies in the liver.

Goldstein 1983,3ed.p.456.

Page 37: Biokimia Sistem Kardiovaskuler

The major energy metabolism pathways.

Voet 1995,2nd ed.785-787

Fig 6.

Page 38: Biokimia Sistem Kardiovaskuler
Page 39: Biokimia Sistem Kardiovaskuler

3. Cholesterol and Lipoprotein 3. Cholesterol and Lipoprotein Turnover correlated with Turnover correlated with

atherosclerosis (CHD)atherosclerosis (CHD)About two thirds of the cholesterol=ch in the blood is found in LDL. The normal total ch content is 3.1 to 5.7 mM in blood serum, of which roughly one fourth is free ch in the surface of various lipoproteins, and the balance is cholesteryl esters in the lipoprotein cores.

Page 40: Biokimia Sistem Kardiovaskuler

Cholesterol is regarded as a nasty word by many laymen and by my collaborator because of its association with lipoproteins.

Anything causing accumulation of the lipoproteins rich in cholesteryl ester-chylomicron remnants, IDLs, or LDLs –is almost certain to cause severe atherosclerosis. However, the engulfment of LDLs is a normal device

Page 41: Biokimia Sistem Kardiovaskuler

Ch transporting agent in the blood are LDLs and HDLs

LDL level in blood related to development of atherosclerosis; this result from a chronic inflammatory response that is initiated by the deposition of LDL

LDL serves primarily to carry ch molecules from the liver, where they are synthesize and packaged, through the blood to the body’s cells

Page 42: Biokimia Sistem Kardiovaskuler

HDLs carries ch in the opposite direction. Excess Ch in transported out of the plasma membrane of the body’s cells directly to circulating HDL particles, which carry ch to the liver for excretion.

High blood levels of LDL are associated with increased of heart disease.

High blood levels of HDL are associated with decreased risk, HDL being called ”good cholesterol”

Page 43: Biokimia Sistem Kardiovaskuler

Cholesteryl ester transfer protein (CETP)

Ch molecules can be transferred from HDL to other lipoprotein particles by an enzyme CETP, an activity that tends to lower HDLch levels.Japanese fam: live more than 100 yr and carry mutations in the CETPA number of small-mw CETP inhibitors in clinical trials, found to greatly increase HDL levels in the blood.

Page 44: Biokimia Sistem Kardiovaskuler

Correlation between the response of inhibitors and CHD is currently under investigation

Karp G.2007,5th ed.316-317.

Page 45: Biokimia Sistem Kardiovaskuler

Topic: B. Cardiac marker and Topic: B. Cardiac marker and Thrombus formationThrombus formation

General learning objective.

Student should be able to understand cardiac marker function and thrombus formation

  

Page 46: Biokimia Sistem Kardiovaskuler

Specific learning objectives 

When student have mastered this topic, student should be able to:

1. describe cellular enzyme as biochemical markers of myocardial damage.

2. describe other intracellular protein (non enzyme) as biochemical marker of myocardial damage

3. describe thrombus formation.

Page 47: Biokimia Sistem Kardiovaskuler

Cardiac markers

IntroductionSensitive and specific serologic biomarkers capable of

detecting small infarcts (as little as 1.0 g) of dead tissues that may not have been considered an MI in earlier era.

Kaplan2003 4th ed.572Prerequisite knowledge: enzyme kinetics and blood

clotting. We’ll mainly discuss: cardiac marker and thrombosis.

Page 48: Biokimia Sistem Kardiovaskuler

The cardiac enzymes historically were

- creatine kinase, - aspartate amino transferase

- lactate dehydrogenase.

Page 49: Biokimia Sistem Kardiovaskuler

A specific CK isoenzyme (CK-MB) is a more specific indicator of cardiac muscle damage than total CK, and can be detected in serum soon(1-3 hr)after an MI has occurredCK-MB is not completely specific for myocardium.

Kaplan 2003 4th ed.573.

Aspartate amino transferase (AST) is a less sensitive index of myocardial damage. It is also hepatic enzyme and levels rise following hepatic congestion due to cardiac failure.

Page 50: Biokimia Sistem Kardiovaskuler

Lactate dehydrogenase (LDH) False positive are also problem, but isoenzyme analysis is available. Its main use is in the retrospective Diagnosis of infarction suspected to have occurred some days previously. Hunt 1982 (1) Nr 19-21 Sept.p.915.

Fig.1 Enzyme in serum following an uncomplicated MI

Page 51: Biokimia Sistem Kardiovaskuler

1818

1616

1414

1212

1010

88

66

44

22

11 22 33 44 55 66

En

zym

e ac

tivi

ty (

x-u

pp

er l

imit

E

nzy

me

acti

vity

(x-

up

per

lim

it

valu

e)va

lue)

n days after chest painn days after chest pain

CK-2 = CK-MBCK-2 = CK-MB

CK TotalCK Total

GOTGOT

LDH-1LDH-1

LDH-TotalLDH-Total

Page 52: Biokimia Sistem Kardiovaskuler

Cardiac marker non enzyme

Myoglobin: is a haem-containing protein present in cardiac and skeletal muscle, that also rises early following MI and has also been used in the diagnosis of MI, but is a nonspecific test and appear to offer no significant advantage over CK estimation.

Page 53: Biokimia Sistem Kardiovaskuler

Troponins : are protein that regulate muscle contraction. Isoform of two of these protein T and I isoform, are specific to myocardium, and the introduction of assays for cardiac troponin T (cTNT) and I (cTNI) represents a major development in the biochemical detection of MI. It is possible with troponins to detect infarctions that are orders of magnitude smaller than those detectable with other cardiac marker.

Page 54: Biokimia Sistem Kardiovaskuler

In the early hours following MI myoglobin more sensitive. Also suspected reinfarction cannot reliable be detected by troponins for as much as 2 weeks, since it takes this length of time for troponins to return to normal following an MI

Gaw A.3rd ed.50-51.

Page 55: Biokimia Sistem Kardiovaskuler

Homocysteine: accumulation of homocysteine in toxic level arterial damage. elasticity deminished and narrowed of vessels caused by over growingconnective tissue and deminishing elastic tissue.

Abbot Diag.Sep.1998.12th.ed.

Page 56: Biokimia Sistem Kardiovaskuler

Troponins are most useful 12 hours or more after MI, when their diagnostic sensitivity is 100%, ie MI can be excluded with confidence with a negative (normal) troponin result if the sample is taken 12 hours or more after onset of chest pain. However, despite their many potential roles. Troponins should not be seen as’perfect markers.

Page 57: Biokimia Sistem Kardiovaskuler

Plasminogen Activator Inhibitor (PAI-1)Fibrinolytic hypofunction as an atherogenic factor : Lp(a) & LDL ch increase the synthesis of PAI-1 in endothelium

Abbot Diag.April 1998.11th ed.

Page 58: Biokimia Sistem Kardiovaskuler

Biomarker of Congestive Heart Failure

Atrial Natriuretic Peptide (ANP) The atrial myocardium secretes ANP when

stretched. In response to high cardiac filling response,specialized myocytes in the atria secrete ANP.ANP increases excretion of salt and water by renal tubules.It also has a small vasodilating effect.

Page 59: Biokimia Sistem Kardiovaskuler

Brain Natriuretic Peptide (BNP)

Ventricel similar secrete BNP, which increases in heart failure. Level of BNP may be used as a blood test for heart failure.

Fagan 2002. 2nd ed.15,62.

Page 60: Biokimia Sistem Kardiovaskuler

Thrombus formation

Pathological clottingA clot is called a thrombus.The occlusion of the vessel is a thrombosis.Three types of thrombi: -red thrombus : consist rbc and fibrin; ,stasis

(eg.veins), -white thrombus: consist platelets and

fibrin,poor in rbc, blood flow is rapid (eg.arteries)

-disseminated fibrin deposit in capillaries. Murray K, 25th ed.752.

--

Page 61: Biokimia Sistem Kardiovaskuler

Atherosclerotic plaque formation is initiated by various types of injury to the endothelial cells that line the vessel, including damage inflicted by oxygen free radicals that chemically alter the LDL-ch particles. The injured endothelium acts as an attractant for white blood cells (leucocytes) and macrophages, which migrate beneath the endothelium and remain there.

Page 62: Biokimia Sistem Kardiovaskuler

The macrophages ingest the ox-LDL, which becomes deposited in the cytoplasm as cholesterol-rich fatty droplets. These cells are referred to as macrophage foam cells. Substances released by the macrophage stimulate the proliferation of smooth muscle cells, which produce a dense, fibrous connective tissue matrix (fibrous cap) that bulges into the arterial lumen. Not only do these bulging lesions restrict blood flow, they are prone to rupture, which can trigger the formation of a blood clot and ensuring heart attack.

Karp G, 3rd ed.316.

Page 63: Biokimia Sistem Kardiovaskuler

Acute Myocardial Infarction (AMI)

Development of atherosclerosis (usually polygenic) Formation of large thrombus in a coronary artery Deprivation of blood supply (ischemia) to myocardium Shift to anaerobic glycolysis decreased synthesis of ATP, depletion of adenine nucleotide pool

Page 64: Biokimia Sistem Kardiovaskuler

Increase of NADH due to inactive terminal electron transport chain; due to lack of oxygen Accumulation of lactic acid and other metabolits, causing increased intracellular osmolarity and altered membrane permeability Decrease of pH in heart muscle cells Increasingly inefficient contraction of heart muscle

Page 65: Biokimia Sistem Kardiovaskuler

Cessation of contraction Activation of membrane phospholipases, degradation of proteins by proteases, influx of Ca2+Death of affected area of heart muscle.

Murray K, 25th ed.855

Page 66: Biokimia Sistem Kardiovaskuler

Conclusion

We have already discussed:A. Metabolic regulation in cardiac organ.1. Heart is a largely aerobic organ2. Cardiac energy metabolism and its

regulation ( glycolysis and lipolysis)3. Cholesterol and Lipoprotein turnover

correlated with atherosclerosis

Page 67: Biokimia Sistem Kardiovaskuler

B. Biomarker and Thrombosis.1. Cardiac markers in Acute Myocardial

Infarction : cellular enzyme and other intracellular protein (non enzyme)

2. Biomarker in the diagnosis of heart failure.

3. Thrombus formation in pathological clotting

Page 68: Biokimia Sistem Kardiovaskuler

References

1. _______, Abbot Diagnostic Editorial 11th ed.1 April 1998

2. _______, Abbot Diagnostic Editorial 12th ed. September 1998

3. Barany MK (2002): Biochemistry of Muscular Contraction, Homepage PHYB- BCHE, 1975-1977. University of Illionis, Chicago

4. Campbell PN, Smith AD (1982): Biochemistry Illustrated, International student ed. Wilture Enterprises (Int.) Ltd/Churchill Livingstone. Hongkong..

Page 69: Biokimia Sistem Kardiovaskuler

5. Fagan T, Sunthareswaran (2002): Cardiovascular System, 2nd ed. Elseviere Science Limited. Mosby. Toronto.

6. Gaw A, et al (2004): Clinical Biochemistry. An Illustrated Colour Text, 3rd ed. Elsevier Limited, Churchill Livingstone. Toronto.

7. Goldstein M (1983): Biochemistry a Functional Approach, 3rd ed. IGAKU-SHOIN/Saunders. Tokyo.

8. Hunt D & Kertes P (1982): The management of acute myocardial infarction in Medicine International.(1) Nr 19-21, September.p.915.Medical Education (International) Ltd. Oxford.Great Britain.

Page 70: Biokimia Sistem Kardiovaskuler

9. Kaplan LA et al (2003): Clinical Chemistry. Theory, Analysis, Correlation, 4th ed. Mosby an Affiliate of Elsevier, USA.

10.Karp G (2007): Cell and Molecular Biology. Concepts and experiments, 5th ed. John Wiley & Sons. Inc.Asia.

11.Murray RK et al (2000): Harper’s Biochemistry, 25th ed. Appleton and Lange, USA.

12.Voet D & Voet JG (1975): Biochemistry, 2nd ed. John Wiley&Sons.Inc.Singapore.